Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment

被引:0
作者
Marie Sanchirico
Amanda Caldwell-Tarr
Pallavi Mudumby
Lobat Hashemi
Robert Dufour
机构
[1] Sanofi,
[2] Comprehensive Health Insights,undefined
[3] A Humana Company,undefined
来源
Neurology and Therapy | 2019年 / 8卷
关键词
Corticosteroid treatment; Disease-modifying therapy; Healthcare resource utilization; Healthcare costs; Medicare; Multiple sclerosis; Relapse;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:121 / 133
页数:12
相关论文
共 93 条
[1]  
Lublin FD(2014)Defining the clinical course of multiple sclerosis: the 2013 revisions Neurology. 83 278-286
[2]  
Reingold SC(2014)Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis BMC Neurol. 14 128-521
[3]  
Cohen JA(2001)Health status and quality of life of people with multiple sclerosis Disabil Rehabil. 23 516-78
[4]  
Simpson RJ(2006)Health problems and health-related quality of life in people with multiple sclerosis Clin Rehabil. 20 67-1286
[5]  
McLean G(2016)Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study Neurology. 86 1279-1295
[6]  
Guthrie B(2016)Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis Neurology. 86 1287-1098
[7]  
Mair F(2008)Comorbidity, socioeconomic status and multiple sclerosis Mult Scler. 14 1091-1532
[8]  
Mercer SW(2011)Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study BMC Neurol. 11 122-367
[9]  
Ford HL(2003)Effect of relapses on development of residual deficit in multiple sclerosis Neurology. 61 1528-1512
[10]  
Gerry E(2010)Evolving expectations around early management of multiple sclerosis Ther Adv Neurol Disord. 3 351-254